Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Lifted by BIT Capital GmbH

BIT Capital GmbH increased its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 41.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,714 shares of the company’s stock after acquiring an additional 50,626 shares during the period. BIT Capital GmbH owned about 0.17% of Day One Biopharmaceuticals worth $2,176,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Day One Biopharmaceuticals by 11.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock valued at $271,000 after purchasing an additional 2,180 shares during the period. R Squared Ltd purchased a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $31,000. Swiss National Bank increased its stake in Day One Biopharmaceuticals by 2.6% in the 4th quarter. Swiss National Bank now owns 117,800 shares of the company’s stock valued at $1,493,000 after buying an additional 3,000 shares during the period. Teacher Retirement System of Texas lifted its position in Day One Biopharmaceuticals by 20.9% in the 4th quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company’s stock worth $226,000 after buying an additional 3,086 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its stake in shares of Day One Biopharmaceuticals by 16.7% during the 4th quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company’s stock valued at $399,000 after buying an additional 4,500 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DAWN. Bank of America dropped their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. cut their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. HC Wainwright lowered their price target on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Wedbush reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Buy” and a consensus target price of $32.29.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $8.12 on Thursday. Day One Biopharmaceuticals, Inc. has a twelve month low of $7.88 and a twelve month high of $18.07. The business has a 50 day moving average price of $10.77 and a 200 day moving average price of $12.69. The firm has a market cap of $823.00 million, a P/E ratio of -7.88 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. As a group, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock valued at $251,925 in the last quarter. Insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.